Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23andMe Holding Co. - Common Stock (NQ:ME)

0.6063 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 23andMe Holding Co. - Common Stock

< Previous 1 2 3 4 Next >
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
Receives Court Approval for First Day Motions to Support Ongoing Business Operations 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches New Genetic Report on Osteoporosis
Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Special Committee Announces Exploration of Strategic Alternatives
From 23andMe, Inc.
Via GlobeNewswire
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology
23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care 
From 23andMe, Inc.
Via GlobeNewswire
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
From 23andMe, Inc.
Via GlobeNewswire
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
From 23andMe, Inc.
Via GlobeNewswire
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Regains Compliance With Nasdaq Listing Requirements
From 23andMe, Inc.
Via GlobeNewswire
23andMe Appoints Three New Independent Directors to Board
From 23andMe, Inc.
Via GlobeNewswire
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
The new African American Genetic Groups feature traces customers' ancestral connections from before the early-to-mid-20th century migrations to more than 200 communities in Southern states 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Completion of 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Mathew Knowles as New Brand Ambassador
Collaboration to help increase awareness of the power of genetic testing when it comes to learning about personal health risks 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics 
From 23andMe, Inc.
Via GlobeNewswire
Independent Directors of 23andMe Resign from Board
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
From 23andMe, Inc.
Via GlobeNewswire
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population 
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
From 23andMe, Inc.
Via GlobeNewswire
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
In conjunction with this new offering, 23andMe, Lemonaid Health’s parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Reports First Quarter Fiscal 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Special Committee responds to CEO’s take-private proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces CEO’s Take-Private Proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q1 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS